Interestingly, it was been recently shown that the combined inhibition of EZH2 and DNMTs re-sensitizes IMiD-resistant myeloma cells to lenalidomide and pomalidomide without altering the expression levels of the cereblon pathway members (CRBN, IKZF1, IKZF3, IRF4), by a mechanism that seems to involve SMAD3 [162]. Here, EZH2 is linked to plasma cell myeloma.